CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib : vimarsana.com

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Related Keywords

Texas , United States , North Carolina , Houston , Johnh Strickler , Ashling Wahner , Michael Leung , Margot Oneill , Arvindn Dasari , Facebook , University Of Texas Md Anderson Cancer Center , Twitter , Duke Cancer Institute , Linkedin , Division Of Cancer Medicine , Duke Cancer Institute In Durham , Live On Air , Taiho Pharmaceutical , Onclive Inside , Medical Oncology , Cancer Center , Cancer Medicine , Margoto Neill , Duke Cancer , Onclive On Air , Apple Podcasts , Google Podcasts , Amazon Music , D , Harmd , Cop , S , A C , Hs , Patients With Colorectal Cancer ,